Augustina Isioma Ikusemoro: Kell vs RhD Sensitization – The Difference in RBC Destruction
Augustina Isioma Ikusemoro, Hematology and Transfusion Medicine Specialist at Sharjah Blood Transfusion and Research Center, shared a post on LinkedIn:
“Anti-D destroys red cells.
Anti-K stops them from being made.
That difference can change everything in fetal survival.
Most clinicians are trained to recognize RhD sensitization as a major cause of Hemolytic Disease of the Fetus and Newborn (HDFN).
But fewer appreciate that Kell sensitization can be equally — and sometimes more — dangerous.
Here’s why this matters
While RhD antibodies destroy circulating fetal red blood cells, Anti-K antibodies suppress fetal red cell production at the bone marrow level.
This means:
- RhD sensitization leads to hemolysis
- Kell sensitization leads to erythropoiesis suppression
And clinically, that distinction is critical.
In RhD HDFN, anemia develops because red cells are destroyed in the fetal spleen.
In Kell-mediated HDFN, anemia develops because red cells are never produced in adequate numbers in the first place.
The result?
- Earlier onset anemia
- Lower reticulocyte counts
- Less predictable disease progression
- Severe fetal compromise even with low antibody titers
Unlike RhD disease — where bilirubin levels often reflect severity — Kell disease can progress silently until fetal anemia becomes critical.
This is why Anti-K detection during pregnancy must always trigger enhanced fetal surveillance.
And why transfusion services must prioritize:
- K- antigen matching for sensitized patients
- Prevention of alloimmunization in women of child-bearing age
- Extended phenotype awareness beyond ABO and RhD
Because transfusion safety doesn’t stop at compatibility.
It continues with anticipation.
Blood Doki
Advancing transfusion safety through education, systems awareness, and clinical insight.”

Stay updated with Hemostasis Today.
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome
-
Nov 17, 2026, 13:37Abdlemewla Ibrahim: Prasugrel vs Ticagrelor in ACS Patients Undergoing PCI
-
Nov 17, 2026, 13:30Stacy E. Croteau: Oral and Dental Care in Pediatric Patients With Bleeding Disorders
-
Nov 17, 2026, 13:19Efe Saglam: Cannabis Use and Cardiac Conduction
-
Nov 17, 2026, 10:41Elena Petkovic։ Highlights from the ISBT–WHO Plasma Management Workshop
-
Nov 17, 2026, 10:30Cheng-Hock Toh: Haematology Is Everywhere – But Is It Recognised?
-
Nov 17, 2026, 10:23Akshat Jain: The Importance of Knowing Your Sickle Cell Status
-
Nov 17, 2026, 10:12Caitlin Raymond: What Does Apheresis Really Cost?
-
Nov 17, 2026, 05:47Multidisciplinary Teams Kick Off SAHF MASAC ES 2026 with Pre-Symposium Workshops – South African Haemophilia Foundation